NCT05426148View on ClinicalTrials.gov

Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female

PHASE4CompletedINTERVENTIONAL
Enrollment

540

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

August 1, 2020

Study Completion Date

April 30, 2021

Conditions
Cervical Intraepithelial NeoplasiaCervical CancerVaginal Intraepithelial NeoplasiaVulvar Intraepithelial NeoplasiaPersistent Infection
Interventions
BIOLOGICAL

Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®

The bivalent HPV 16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with aluminum adjuvant.

Trial Locations (1)

224200

Dongtai City Center for Disease Control and Prevention Dongtai, Jiangsu, Dongtai

All Listed Sponsors
collaborator

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

collaborator

Dongtai City Centers for Disease Control and Prevention

UNKNOWN

lead

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

NCT05426148 - Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female | Biotech Hunter | Biotech Hunter